After being a customer for years, I was charged 300CHF penalty for not staying with VTX when I moved to another canton. Then they claimed not to have received modem bespite sending by register mail to address on the box.
Cheap provider. unfortunately the range of the 4G is greatly reduced in arlesheim Z.b 1Balken
Comunication over the phone proves to be difficult as it usually has French speaking staff members.
Otherwise I drive O.K with it
After I had a question about email setup, I was informed that there was no longer any support via email or phone for free customers. Here, services are clandestinely reduced, a no-go!
Just a joke mail Surfer for 5 hours without function, Hotliene unavailable, will do all kuenden and switch to another provider
I have been a VTX customer for years. The internet is very stable and I reach the promised bandwidth (even about 10% more). The highlight, however, is the telephony (VoIP), which works perfectly for years. The quality is very good. The customer access is very well opened and easy to use. I am also very satisfied with the TV offer.
The cost of the Internet should be priced quietly approximated to the competition, for the telephony they are ok, I find TV quite cheap. I can recommend it.
Dirt shop! Worthy incredible! Brutally bad, brutally incompetent! Forget the purchased Blender!
DataComm (Schweiz) AG, DataComm Deutschland GmbH is a Swiss biotech start-up that is dedicated to developing innovative antibiotics for the treatment of life-threatening, multi-drug resistant infections. The company was founded with the aim of addressing the growing problem of antibiotic resistance, which has become a major public health concern worldwide.
Antibiotic resistance occurs when bacteria evolve and develop mechanisms to resist the effects of antibiotics. This can happen naturally over time, but it is also accelerated by the overuse and misuse of antibiotics in humans and animals. As a result, many common infections are becoming increasingly difficult to treat with existing antibiotics.
DataComm (Schweiz) AG, DataComm Deutschland GmbH recognizes this urgent need for new and effective antibiotics. The company's research focuses on identifying novel targets for antibacterial drugs and developing new compounds that can overcome antibiotic resistance mechanisms.
One key area of focus for DataComm (Schweiz) AG, DataComm Deutschland GmbH is Gram-negative bacteria. These types of bacteria are particularly challenging to treat because they have an outer membrane that makes it difficult for drugs to penetrate into the cell. However, Gram-negative bacteria are responsible for many serious infections such as pneumonia, sepsis, and urinary tract infections.
To address this challenge, DataComm (Schweiz) AG, DataComm Deutschland GmbH has developed a proprietary platform technology called "Gram-Negative Antibiotic Discovery" or GNAD. This technology enables the identification of novel targets within Gram-negative bacteria that can be exploited by new antibacterial agents.
In addition to its research efforts in antibiotic discovery and development, DataComm (Schweiz) AG also provides contract research services to other companies in the biotech industry. These services include assay development and screening using its proprietary GNAD platform technology.
The team at DataComm (Schweiz) AG consists of experienced scientists with expertise in microbiology, biochemistry, pharmacology and medicinal chemistry. They work closely together on all aspects of drug discovery from target identification through lead optimization to preclinical testing.
Overall datacomm Schweiz ag & datacomm deutschland gmbh is committed towards discovering innovative solutions against multi-drug resistant bacterial infection which poses significant threat towards human health globally . With their cutting-edge technologies , experienced team & commitment towards scientific excellence , they are poised towards making significant contribution towards global healthcare sector .
selmod.com
